AI Article Synopsis
- New COVID-19 treatments are urgently needed due to rising cases and new strains threatening vaccine effectiveness, with cell therapy, specifically iNKT cells, showing promise in tackling the disease.
- Researchers developed a method to produce allogeneic HSC-engineered iNKT cells, enhancing their availability for treatment through engineered hematopoietic stem cells and culture techniques.
- Preclinical results indicate that these engineered cells resemble natural iNKT cells, effectively kill SARS-CoV-2 infected cells, reduce inflammation, and are safe for use without causing graft-versus-host disease (GvHD).
Article Abstract
Background: New COVID-19 treatments are desperately needed as case numbers continue to rise and emergent strains threaten vaccine efficacy. Cell therapy has revolutionized cancer treatment and holds much promise in combatting infectious disease, including COVID-19. Invariant natural killer T (iNKT) cells are a rare subset of T cells with potent antiviral and immunoregulatory functions and an excellent safety profile. Current iNKT cell strategies are hindered by the extremely low presence of iNKT cells, and we have developed a platform to overcome this critical limitation.
Methods: We produced allogeneic HSC-engineered iNKT (HSC-iNKT) cells through TCR engineering of human cord blood CD34 hematopoietic stem cells (HSCs) and differentiation of these HSCs into iNKT cells in an Ex Vivo HSC-Derived iNKT Cell Culture. We then established in vitro SARS-CoV-2 infection assays to assess HSC-iNKT cell antiviral and anti-hyperinflammation functions. Lastly, using in vitro and in vivo preclinical models, we evaluated HSC-iNKT cell safety and immunogenicity for off-the-shelf application.
Results: We reliably generated HSC-iNKT cells at high-yield and of high-purity; these resulting cells closely resembled endogenous human iNKT cells in phenotypes and functionalities. In cell culture, HSC-iNKT cells directly killed SARS-CoV-2 infected cells and also selectively eliminated SARS-CoV-2 infection-stimulated inflammatory monocytes. In an in vitro mixed lymphocyte reaction (MLR) assay and an NSG mouse xenograft model, HSC-iNKT cells were resistant to T cell-mediated alloreaction and did not cause GvHD.
Conclusions: Here, we report a method to robustly produce therapeutic levels of HSC-iNKT cells. Preclinical studies showed that these HSC-iNKT cells closely resembled endogenous human iNKT cells, could reduce SARS-CoV-2 virus infection load and mitigate virus infection-induced hyperinflammation, and meanwhile were free of GvHD-risk and resistant to T cell-mediated allorejection. These results support the development of HSC-iNKT cells as a promising off-the-shelf cell product for treating COVID-19; such a cell product has the potential to target the new emerging SARS-CoV-2 variants as well as the future new emerging viruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935266 | PMC |
| http://dx.doi.org/10.1186/s13287-022-02787-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers.
iScience
September 2022
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated by alloreactive T cells; however, the same T cells also mediate GvHD, a severe side effect limiting the widespread application of allo-HSCT in clinics. Invariant natural killer T (iNKT) cells can ameliorate GvHD while preserving GvL effect, but the clinical application of these cells is restricted by their scarcity. Here, we report the successful generation of third-party HSC-engineered human iNKT (HSC-iNKT) cells using a method combining HSC gene engineering and HSC differentiation.
View Article and Find Full Text PDFDevelopment of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention.
Stem Cell Res Ther
March 2022
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Article Synopsis
- New COVID-19 treatments are urgently needed due to rising cases and new strains threatening vaccine effectiveness, with cell therapy, specifically iNKT cells, showing promise in tackling the disease.
- Researchers developed a method to produce allogeneic HSC-engineered iNKT cells, enhancing their availability for treatment through engineered hematopoietic stem cells and culture techniques.
- Preclinical results indicate that these engineered cells resemble natural iNKT cells, effectively kill SARS-CoV-2 infected cells, reduce inflammation, and are safe for use without causing graft-versus-host disease (GvHD).
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Cell Rep Med
November 2021
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Cell-based immunotherapy has become the new-generation cancer medicine, and "off-the-shelf" cell products that can be manufactured at large scale and distributed readily to treat patients are necessary. Invariant natural killer T (iNKT) cells are ideal cell carriers for developing allogeneic cell therapy because they are powerful immune cells targeting cancers without graft-versus-host disease (GvHD) risk. However, healthy donor blood contains extremely low numbers of endogenous iNKT cells.
View Article and Find Full Text PDFDevelopment of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.
Cell Stem Cell
October 2019
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:
Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels of iNKT cells for a patient's lifetime. Using a human HSC engrafted mouse model and a human iNKT TCR gene engineering approach, we demonstrated the efficient and long-term generation of HSC-iNKT cells in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!